In this review:
Osimertinib vs EGFR-TKI as first-line therapy for EGFR-m advanced NSCLC
Nivolumab + ipilimumab vs platinum-doublet CT first-line for advanced NSCLC
ctDNA for early detection of disease progression in advanced NSCLC
Bevacizumab ± erlotinib in untreated advanced EGFR-m NSCLC
Pembrolizumab vs single agent CT for advanced pre-treated MPM
OS with atezolizumab vs platinum-based CT, front-line in PD-L1-selected NSCLC
Ceritinib in patients with ALK+ NSCLC metastatic to the brain
Tissue TMB & outcomes with pembrolizumab in PD-L1+ advanced NSCLC
Pembrolizumab plus platinum-based CT in metastatic NSCLC
Outcomes with durvalumab plus platinum-etoposide in extensive-stage SCLC
Atezolizumab + carboplatin + etoposide in extensive-stage SCLC
Please login below to download this issue (PDF)